KLRK1 and Miyoshi myopathy: NKG2D CAR T-cells obtained no clinical response or side effects, which may be because CAR T-cells were infused without prior lympho-depletion, or, as found in preclinical work, NKG2D CAR NK-cells rather than T-cells were effective in eliminating MM cells (NCT02203825) (42, 45).